viewAlliance Pharma PLC

Alliance Pharma says profit to be marginally ahead of forecasts despite coronavirus pandemic challenges

The healthcare products firm also said its cash flow in 2020 has "remained very strong", bolstered by favourable movements in net working capital

Alliance Pharma PLC - Alliance Pharma says profit to be marginally ahead of forecasts despite pandemic challenges

Alliance Pharma PLC (LON:APH) has said its underlying pre-tax profit for 2020 is expected to be “marginally ahead of market expectations” as its consumer healthcare brands continued to perform strongly despite the impact of the coronavirus (COVID-19) pandemic.

In a trading update for the year to December 31, 2020, the AIM-listed group said its see-through revenues for the year were down 5% at £137.5mln as a result of the pandemic.

READ: Alliance Pharma beefs up US arm with menopause treatment supplement

One bright spot were revenues for consumer products, which rose 1% to £93mln year-on-year, although this was offset by a 14% decline in prescription medicines to £44.5mln as COVID-19 impacted the delivery of routine treatments.

Despite the revenue decline, Alliance said cash flow in the year “remained very strong” at £34.1mln, up from £29.1mln last year, with second-half cash flows being “significantly stronger” than the first.

The company also highlighted that its acquisition of US healthcare firm Biogix Inc last month for US$110mln “creates scale” for its US business and is expected to be earnings enhancing in 2021 and “significantly earnings enhancing” from 2022.

"The group continued to deliver a robust operational and financial performance in the second half of 2020, despite the ongoing challenges of the pandemic. Whilst top-line revenue growth has been constrained overall, our consumer healthcare business has performed well given the market backdrop and we have seen some strong performances from a number of our brands, in particular Kelo-cote. Our free cash flow has remained very strong, enabling us to pay down more of our debt ahead of completing the Biogix acquisition close to the end of the year”, Alliance chief executive Peter Butterfield said in a statement.

"We're particularly pleased that we managed to complete such a large and strategically significant acquisition at the end of 2020, in addition to maintaining the performance of the base business as we navigated our way through the challenges of COVID-19. As we progress into 2021, we look forward to regaining the strong momentum and revenue growth of recent years, and to benefiting from the additional growth opportunities that Amberen brings into the group", he added.

The company’s shares jumped 2.4% to 89.3p in early deals on Wednesday.

Quick facts: Alliance Pharma PLC

Price: 84 GBX

Market: AIM
Market Cap: £447.97 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Alliance Pharma PLC named herein, including the promotion by the Company of Alliance Pharma PLC in any Content on the Site, the Company...


Market report: FTSE fights back after bruising start to week

The FTSE is fighting back after enduring the worst sell-off since June on Monday.  UK Prime Minister Boris Johnson will address the nation today about more possible lockdowns after announcing pubs, bars, restaurants and other hospitality venues in England must close by...

on 22/9/20

2 min read